Biotech Company Reports Breakthrough in Glioblastoma Drug Trials
1 report, 1 independent
Updated Oct 9
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oncopeptides AB announced results from its OP-701 clinical study, which evaluates its Peptide Drug Conjugate platform for glioblastoma. The study found that the drug successfully penetrated the human blood-brain barrier in the first three treated patients. The first patient received five monthly doses without any major drug-related toxicity.
From finanznachrichten.de
Why it matters
The findings provide a strong indication of a clinical proof-of-concept for the PDC platform in solid brain tumors. This is significant because the blood-brain barrier prevents more than 90 percent of conventional systemic cancer drugs from reaching the brain.
From finanznachrichten.de
Who's involved
- Oslo University HospitalHospital where a clinical study was conducted
Keep exploring
The entities involved
-
Oslo University Hospital
hospital in Norway
Nothing else this week.